Postmarketing Adverse Event Reporting Compliance Services

Postmarketing requirements typically include complaint handling, adverse event and malfunction reporting, post-market surveillance, trend analysis, CAPA linkage, and ongoing documentation updates. For medical device manufacturers, obligations may also include MDR or vigilance submissions, PMS reports, PSURs, labeling updates, and change assessments. Requirements vary by market, but regulators consistently expect timely decisions, documented rationale, and traceable records.

A postmarketing report is a regulatory submission or formal compliance document prepared after a product is on the market. It may include adverse event reports, vigilance reports, Medical Device Reports, PMS reports, PSURs, or other safety-related updates. These reports help regulators monitor device performance, identify emerging risks, and verify that manufacturers are actively managing safety and compliance obligations.

An adverse event becomes reportable when it meets the criteria defined by the applicable regulator, such as FDA MDR rules under 21 CFR Part 803 or EU MDR vigilance requirements. Key factors include seriousness, device involvement, malfunction recurrence risk, and whether the event could lead to death or serious deterioration in health. A structured assessment process is essential to support timely, defensible reporting decisions.

Submission timelines depend on the jurisdiction and event severity. Some events require rapid reporting within days, while others follow standard reporting windows defined by the regulator. Manufacturers need procedures that support prompt intake, triage, investigation, and decision-making so deadlines are not missed. Delays often occur when complaint handling, reportability review, and documentation ownership are not clearly coordinated.

Complaint handling is often the starting point for adverse event reporting because complaints may contain the first evidence of a reportable malfunction, injury, or safety signal. A compliant process should classify complaints accurately, initiate investigations on time, assess reportability consistently, and document closure clearly. Regulators expect complaint files to connect directly to MDR, vigilance, CAPA, and risk management activities where applicable.

Yes. Elexes supports manufacturers operating across FDA, EU MDR, TGA, Health Canada, and other regulatory frameworks. This includes reportability assessments, adverse event submissions, PMS governance, and authority response support. Global coordination matters because the same event may trigger different timelines, thresholds, and documentation expectations in different markets, requiring a harmonized but jurisdiction-specific compliance approach.

A reportability decision should be supported by the complaint record, event details, investigation findings, device history, risk management references, applicable regulatory criteria, and a documented rationale for the final determination. Where reporting is required, submission copies and follow-up correspondence should also be retained. Regulators look for consistency between the decision record, the underlying evidence, and related quality system outputs such as CAPA or PMS trending.

Yes. Outsourced RAQA support can provide continuous oversight for complaint review, reportability assessments, PMS activities, document control, and regulatory correspondence without requiring a full in-house team. This model is especially useful for growing manufacturers, lean regulatory teams, or companies managing multiple markets. It helps maintain continuity, reduce missed deadlines, and keep post-market obligations active between major submissions or audits.